相似文献
1
The 2010 Philip S. Portoghese Medicinal Chemistry Lectureship: addressing the "core issue" in the design of estrogen receptor ligands.2010年菲利普·S·波托盖斯药物化学讲座：探讨雌激素受体配体设计中的“核心问题”
J Med Chem. 2011 Aug 11;54(15):5271-82. doi: 10.1021/jm200801h. Epub 2011 Jul 11.
2
Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis.
J Med Chem. 2004 Dec 16;47(26):6435-8. doi: 10.1021/jm049194+.
3
Design and evaluation of fragment-like estrogen receptor tetrahydroisoquinoline ligands from a scaffold-detection approach.基于骨架探测策略的片段样雌激素受体四氢异喹啉配体的设计与评价。
J Med Chem. 2011 Apr 14;54(7):2005-11. doi: 10.1021/jm1011116. Epub 2011 Mar 7.
4
[Towards bisphenols without hormonal effects].
Med Sci (Paris). 2013 Jan;29(1):14-7. doi: 10.1051/medsci/2013291004. Epub 2013 Jan 25.
5
Steroidal bivalent ligands for the estrogen receptor: design, synthesis, characterization and binding affinities.用于雌激素受体的甾体二价配体：设计、合成、表征及结合亲和力
Bioorg Med Chem. 2009 May 15;17(10):3528-35. doi: 10.1016/j.bmc.2009.04.016. Epub 2009 Apr 12.
6
Computational insights into the mechanism of ligand unbinding and selectivity of estrogen receptors.雌激素受体配体解离机制及选择性的计算洞察
J Phys Chem B. 2009 Jul 30;113(30):10436-44. doi: 10.1021/jp903785h.
7
Salicylaldoxime moiety as a phenolic "A-Ring" substitute in estrogen receptor ligands.水杨醛肟部分作为雌激素受体配体中酚类“A环”替代物。
J Med Chem. 2001 Nov 22;44(24):4288-91. doi: 10.1021/jm010948j.
8
Protein structure-based design, synthesis strategy and in vitro pharmacological characterization of estrogen receptor alpha and beta selective compounds.基于蛋白质结构的雌激素受体α和β选择性化合物的设计、合成策略及体外药理学特性研究
Ernst Schering Res Found Workshop. 2004(46):47-62. doi: 10.1007/978-3-662-05386-7_4.
9
Synthesis and crystal structure of a phosphorylated estrogen receptor ligand binding domain.一种磷酸化雌激素受体配体结合结构域的合成与晶体结构
Chembiochem. 2010 Nov 2;11(16):2251-4. doi: 10.1002/cbic.201000532.
10
Aliphatic substitution of o-carboranyl phenols enhances estrogen receptor beta selectivity.邻碳硼烷苯酚的脂肪族取代增强了雌激素受体β选择性。
Chem Pharm Bull (Tokyo). 2014;62(4):386-91. doi: 10.1248/cpb.c13-00796.
引用本文的文献
1
Endocrine-Disrupting Activities of Flavones on Steroid Receptors: Structural Requirements and Synthesis of Novel Flavone with Improved Estrogenic Activity.黄酮类化合物对类固醇受体的内分泌干扰活性：结构要求及具有增强雌激素活性的新型黄酮类化合物的合成
Biomedicines. 2025 Mar 19;13(3):748. doi: 10.3390/biomedicines13030748.
2
Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer.发现针对内分泌抵抗性乳腺癌的新型共价选择性雌激素受体降解剂。
Acta Pharm Sin B. 2023 Dec;13(12):4963-4982. doi: 10.1016/j.apsb.2023.05.005. Epub 2023 May 12.
3
A New Chemotype of Chemically Tractable Nonsteroidal Estrogens Based on a Thieno[2,3-]pyrimidine Core.基于噻吩并[2,3-]嘧啶核心的可化学处理的非甾体雌激素的一种新化学类型。
ACS Med Chem Lett. 2022 Jun 10;13(7):1151-1158. doi: 10.1021/acsmedchemlett.2c00180. eCollection 2022 Jul 14.
4
Heterodimeric GW7604 Derivatives: Modification of the Pharmacological Profile by Additional Interactions at the Coactivator Binding Site.异二聚体 GW7604 衍生物：通过在共激活剂结合位点的附加相互作用修饰药理学特性。
J Med Chem. 2021 May 13;64(9):5766-5786. doi: 10.1021/acs.jmedchem.0c02230. Epub 2021 Apr 27.
5
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.作为有效的泛丝状病毒抑制剂的雌激素受体配体的筛选和反向工程。
J Med Chem. 2020 Oct 8;63(19):11085-11099. doi: 10.1021/acs.jmedchem.0c01001. Epub 2020 Sep 22.
6
Rational design and optimization of selenophenes with basic side chains as novel potent selective estrogen receptor modulators (SERMs) for breast cancer therapy.合理设计与优化带有碱性侧链的硒吩类化合物，作为用于乳腺癌治疗的新型强效选择性雌激素受体调节剂（SERM）。
Medchemcomm. 2017 May 24;8(7):1485-1497. doi: 10.1039/c7md00163k. eCollection 2017 Jul 1.
7
A trisubstituted pyrazole derivative reduces DMBA-induced mammary tumor growth in rats by inhibiting estrogen receptor-α expression.三取代吡唑衍生物通过抑制雌激素受体-α表达减少 DMBA 诱导的大鼠乳腺肿瘤生长。
Mol Cell Biochem. 2018 Dec;449(1-2):137-144. doi: 10.1007/s11010-018-3350-8. Epub 2018 May 18.
8
Emerging Estrogenic Pollutants in the Aquatic Environment and Breast Cancer.水生环境中的新兴雌激素污染物与乳腺癌
Genes (Basel). 2017 Sep 15;8(9):229. doi: 10.3390/genes8090229.
9
Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial.采用新型放射性示踪剂 F-4FMFES 的正电子发射断层扫描（PET）对雌激素受体阳性乳腺癌患者进行的雌激素受体评估的改善：一项正在进行的 II 期临床试验。
J Nucl Med. 2018 Feb;59(2):197-203. doi: 10.2967/jnumed.117.194654. Epub 2017 Aug 10.
10
Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells.具有新型侧链的金刚烷基抗雌激素在抑制乳腺癌细胞中雌激素受体介导的活性方面展现出一系列活性。
J Med Chem. 2017 Jul 27;60(14):6321-6336. doi: 10.1021/acs.jmedchem.7b00585. Epub 2017 Jul 14.
本文引用的文献
1
An ADIOL-ERβ-CtBP transrepression pathway negatively regulates microglia-mediated inflammation.ADIO1-ERβ-CtBP 转录抑制通路负调控小胶质细胞介导的炎症反应。
Cell. 2011 May 13;145(4):584-95. doi: 10.1016/j.cell.2011.03.050.
2
Structure of estradiol metal chelate and estrogen receptor complex: the basis for designing a new class of selective estrogen receptor modulators.雌二醇金属螯合物和雌激素受体复合物的结构：设计新型选择性雌激素受体调节剂的基础。
J Med Chem. 2011 May 26;54(10):3575-80. doi: 10.1021/jm200192y. Epub 2011 Apr 19.
3
Synthesis and investigations on the oxidative degradation of C3/C5-alkyl-1,2,4-triarylpyrroles as ligands for the estrogen receptor.C3/C5-烷基-1,2,4-三芳基吡咯作为雌激素受体配体的氧化降解合成与研究。
ChemMedChem. 2011 May 2;6(5):794-803. doi: 10.1002/cmdc.201000537. Epub 2011 Mar 17.
4
Estrogen receptors: therapies targeted to receptor subtypes.雌激素受体：针对受体亚型的治疗方法。
Clin Pharmacol Ther. 2011 Jan;89(1):44-55. doi: 10.1038/clpt.2010.226. Epub 2010 Dec 1.
5
Identification of ligand-selective peptide antagonists of the mineralocorticoid receptor using phage display.利用噬菌体展示技术鉴定盐皮质激素受体的配体选择性肽拮抗剂。
Mol Endocrinol. 2011 Jan;25(1):32-43. doi: 10.1210/me.2010-0193. Epub 2010 Nov 24.
6
Genomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs.雌激素受体 alpha 和细胞外信号调节激酶 2 在调节基因和增殖程序中的基因组协作。
Mol Cell Biol. 2011 Jan;31(1):226-36. doi: 10.1128/MCB.00821-10. Epub 2010 Oct 18.
7
Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice.非核雌激素受体α信号促进心血管保护，但不促进小鼠子宫或乳腺癌生长。
J Clin Invest. 2010 Jul;120(7):2319-30. doi: 10.1172/JCI38291. Epub 2010 Jun 23.
8
Estrogen receptor β ligands: recent advances and biomedical applications.雌激素受体 β 配体：最新进展及生物医学应用。
Med Res Rev. 2011 May;31(3):364-442. doi: 10.1002/med.20186.
9
Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection.雌激素受体α和β的全基因组染色质结合动力学：相互限制与竞争位点选择
Mol Endocrinol. 2010 Jan;24(1):47-59. doi: 10.1210/me.2009-0252. Epub 2009 Nov 6.
10
Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands.雄激素受体上蛋白质相互作用表面的差异呈现决定了结合配体的药理作用。
Chem Biol. 2009 Apr 24;16(4):452-60. doi: 10.1016/j.chembiol.2009.01.016.
Zotero 插件